CCM
TBPH icon

CAAS Capital Management’s Theravance Biopharma TBPH Stock Holding History

CAAS Capital Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-61,450
Closed -$892K – 1111
2021
Q2 		$892K Buy
+61,450
New +$1.15M 0.02% 610

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

CAAS Capital Management's TBPH Position: Q3 2021 in Review

CAAS Capital Management sold out of Theravance Biopharma (TBPH) in Q3 2021, closing a stake of 61,450 shares — an estimated $892K sold.

CAAS Capital Management first reported a position in TBPH in Q2 2021 and held it in 1 quarter. The position peaked at $892K in Q2 2021. 119 funds tracked by Wall St. Rank hold TBPH as of Q3 2021.

  • CAAS Capital Management reported no remaining Theravance Biopharma position as of Q3 2021 after selling out during the quarter.
  • CAAS Capital Management sold 61,450 Theravance Biopharma shares in Q3 2021, an estimated $892K.
  • CAAS Capital Management first reported a position in Theravance Biopharma in Q2 2021 and held it in 1 quarter.
  • CAAS Capital Management's Theravance Biopharma position peaked at $892K in Q2 2021.
  • 119 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2021.

Based on CAAS Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.